Real-World Efficacy of Second-Line Toripalimab
•Clarify the real-world efficacy and safety of second-line Toripalimab with advanced nonesmall-cell lung cancer in a retrospective multicenter trial.
•Nonadenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS).
•PFS and overall survival (OS) were longer in patients with pembrolizumab-related adverse events;however, PFS and OS were shorter in patients with interstitial lung disease